Genfit S.A. (NASDAQ:GNFT) Sees Significant Growth in Short Interest

Genfit S.A. (NASDAQ:GNFT) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 63,400 shares, an increase of 6.0% from the December 15th total of 59,800 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 10,100 shares, the days-to-cover ratio is presently 6.3 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Genfit in a research report on Friday, October 11th.

Genfit Price Performance

GNFT opened at $3.51 on Tuesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74. The company’s 50 day simple moving average is $3.94 and its 200-day simple moving average is $4.49. Genfit has a one year low of $3.33 and a one year high of $6.42.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.